Firstly, despite our focus on patients with oligo-residual NSCLC and EGFR/ALK wildtype, there remains inherent heterogeneity, such as driver gene alteration status, histology, overall disease burden, metastatic disease interval, and previous systemic therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.